We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein Q4 Earnings Preview: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
HSIC is set to report Q4 2025 results on Feb. 24, with revenues projected to rise 4.5% year over year.
Henry Schein's Global Specialty Products revenues are expected to grow 5.9% on implant strength.
HSIC's Global Technology sales are projected to jump 9.7% on SaaS and cloud momentum.
Henry Schein, Inc. (HSIC - Free Report) is scheduled to release fourth-quarter 2025 results on Feb. 24, before the opening bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.38, which surpassed the Zacks Consensus Estimate by 8.66%. Henry Schein’s earnings beat estimates in two of the trailing four quarters, matched once and missed on one occasion. The average surprise is 1.37%.
Q4 Estimates for HSIC
The Zacks Consensus Estimate for revenues is pegged at $3.33 billion, which suggests an increase of 4.5% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pinned at $1.30, indicating a year-over-year improvement of 9.2%.
Estimate Revision Trend Ahead of HSIC’s Q4 Earnings
Estimates for fourth-quarter earnings have remained constant at $1.30 in the past 90 days.
Here’s a quick overview of the company’s performance leading up to this announcement.
Key Factors Driving HSIC’s Q4 Performance
Global Distribution and Value-Added Services
The segment is likely to have witnessed solid sales momentum across both merchandise and equipment in the fourth quarter of 2025. U.S. merchandise sales may have benefited from targeted promotional programs initiated earlier in the year, which have likely helped Henry Schein continue to increase its U.S. market share, while corporate brand sales may have also remained strong. The sales volume of digital dental equipment is likely to have been robust. The U.S. equipment arena is expected to have benefited from the strong order intake at DS World and the impact of the new online financing program. These developments may have favorably contributed to the company’s fourth-quarter revenues.
Henry Schein’s U.S. Medical business may have seen solid demand for medical products and pharmaceuticals, alongside ongoing momentum in Home Solutions. International dental merchandise and international equipment sales are also likely to have positively impacted revenues. Value-added services sales may have been driven by consulting services, including the eAssist revenue cycle management business.
Our model projects Henry Schein’s Global Distribution and Value-Added Services revenues to increase 3.9% year over year in the fourth quarter.
Global Specialty Products
Within this segment, continued strength in implants and biomaterials, as well as endodontics, is expected to have boosted the fourth-quarter performance. Henry Schein is also likely to have gained share across most implant markets where it has strong positioning. Both S.I.N and Biotech Dental implant systems are expected to have made a solid contribution, supported by growth in the BioHorizons Camlog premium brand.
In the fourth quarter of 2025, U.S. implant and biomaterials sales may have gained from the continued traction of the BioHorizons Tapered Pro Conical implant and the ongoing demand for SmartShape Healers abutment.
Internationally, implant sales across the DACH region and Latin America may have been robust due to patient demand and the execution of the regional team. Henry Schein’s endodontics business is expected to have continued benefiting from expanded sales reach through the company’s U.S. distribution team. We also assume a strong contribution from the Orthopedics specialty business to have supported the company’s top line.
Going by our model, Global Specialty Products’ revenues are expected to increase 5.9% year over year.
Global Technology
Similar to the past quarters, the segment’s sales may have been driven by strong growth in the Core Practice Management System Solutions business, particularly in cloud-based platforms, including Dentrix Ascend in North America and Dentally outside of North America, as well as strong growth in the revenue cycle management offerings, including e-claims, electronic billing and patient messaging. These may have also supported growth in the company’s annual recurring SaaS subscription revenues, alongside higher adoption of transactional services.
Our model estimates indicate Global Technology revenues to grow 9.7% year over year in the fourth quarter of 2025.
What Our Model Suggests for HSIC
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below:
Earnings ESP: Henry Schein has an Earnings ESP of -0.77%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #2. The company is set to release fourth-quarter 2025 results on Feb. 25.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS suggests an increase of 13.9% from the year-ago quarter figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +3.92% and a Zacks Rank #2. The company is set to release fourth-quarter 2025 results on Feb. 24.
GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.24%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies a surge of 26.2% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for an increase of 3.2% from the year-ago quarter’s figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Henry Schein Q4 Earnings Preview: What's in Store for the Stock?
Key Takeaways
Henry Schein, Inc. (HSIC - Free Report) is scheduled to release fourth-quarter 2025 results on Feb. 24, before the opening bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.38, which surpassed the Zacks Consensus Estimate by 8.66%. Henry Schein’s earnings beat estimates in two of the trailing four quarters, matched once and missed on one occasion. The average surprise is 1.37%.
Q4 Estimates for HSIC
The Zacks Consensus Estimate for revenues is pegged at $3.33 billion, which suggests an increase of 4.5% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pinned at $1.30, indicating a year-over-year improvement of 9.2%.
Estimate Revision Trend Ahead of HSIC’s Q4 Earnings
Estimates for fourth-quarter earnings have remained constant at $1.30 in the past 90 days.
Here’s a quick overview of the company’s performance leading up to this announcement.
Key Factors Driving HSIC’s Q4 Performance
Global Distribution and Value-Added Services
The segment is likely to have witnessed solid sales momentum across both merchandise and equipment in the fourth quarter of 2025. U.S. merchandise sales may have benefited from targeted promotional programs initiated earlier in the year, which have likely helped Henry Schein continue to increase its U.S. market share, while corporate brand sales may have also remained strong. The sales volume of digital dental equipment is likely to have been robust. The U.S. equipment arena is expected to have benefited from the strong order intake at DS World and the impact of the new online financing program. These developments may have favorably contributed to the company’s fourth-quarter revenues.
Henry Schein, Inc. Price and EPS Surprise
Henry Schein, Inc. price-eps-surprise | Henry Schein, Inc. Quote
Henry Schein’s U.S. Medical business may have seen solid demand for medical products and pharmaceuticals, alongside ongoing momentum in Home Solutions. International dental merchandise and international equipment sales are also likely to have positively impacted revenues. Value-added services sales may have been driven by consulting services, including the eAssist revenue cycle management business.
Our model projects Henry Schein’s Global Distribution and Value-Added Services revenues to increase 3.9% year over year in the fourth quarter.
Global Specialty Products
Within this segment, continued strength in implants and biomaterials, as well as endodontics, is expected to have boosted the fourth-quarter performance. Henry Schein is also likely to have gained share across most implant markets where it has strong positioning. Both S.I.N and Biotech Dental implant systems are expected to have made a solid contribution, supported by growth in the BioHorizons Camlog premium brand.
In the fourth quarter of 2025, U.S. implant and biomaterials sales may have gained from the continued traction of the BioHorizons Tapered Pro Conical implant and the ongoing demand for SmartShape Healers abutment.
Internationally, implant sales across the DACH region and Latin America may have been robust due to patient demand and the execution of the regional team. Henry Schein’s endodontics business is expected to have continued benefiting from expanded sales reach through the company’s U.S. distribution team. We also assume a strong contribution from the Orthopedics specialty business to have supported the company’s top line.
Going by our model, Global Specialty Products’ revenues are expected to increase 5.9% year over year.
Global Technology
Similar to the past quarters, the segment’s sales may have been driven by strong growth in the Core Practice Management System Solutions business, particularly in cloud-based platforms, including Dentrix Ascend in North America and Dentally outside of North America, as well as strong growth in the revenue cycle management offerings, including e-claims, electronic billing and patient messaging. These may have also supported growth in the company’s annual recurring SaaS subscription revenues, alongside higher adoption of transactional services.
Our model estimates indicate Global Technology revenues to grow 9.7% year over year in the fourth quarter of 2025.
What Our Model Suggests for HSIC
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below:
Earnings ESP: Henry Schein has an Earnings ESP of -0.77%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Key MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #2. The company is set to release fourth-quarter 2025 results on Feb. 25.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS suggests an increase of 13.9% from the year-ago quarter figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +3.92% and a Zacks Rank #2. The company is set to release fourth-quarter 2025 results on Feb. 24.
GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.24%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies a surge of 26.2% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for an increase of 3.2% from the year-ago quarter’s figure.